Marcumar

Phenprocoumon, the active ingredient in Marcumar, is a vitamin K antagonist presented as an oral tablet for oral use. It is employed to prevent thromboembolic events such as deep‑vein thrombosis and stroke in patients with atrial fibrillation, and to treat established venous clotting disorders.

GNH USA supplies Marcumar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows EU GMP standards and provides full regulatory documentation for global distribution.

Marcumar is a vitamin K antagonist used in the management of clotting disorders and related conditions.

- Prevention of thromboembolic events: reduces the risk of clot formation in at‑risk patients. - Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension. - Prevention of stroke in atrial fibrillation: lowers the incidence of embolic stroke in patients with irregular heart rhythm.

Phenprocoumon may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Minor bleeding or bruising: easy bruising, gum bleeding, or nosebleeds. - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Headache or dizziness: transient sensations of light‑headedness.

Serious or Rare Side Effects: - Intracranial hemorrhage: bleeding within the brain, a medical emergency. - Severe gastrointestinal bleeding: blood in stool or vomiting blood. - Skin necrosis: painful skin lesions, often at sites of fat tissue. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Liver enzyme elevation: abnormal liver function tests indicating hepatic stress. - Thrombocytopenia: low platelet count leading to increased bleeding risk.

Before initiating therapy with Marcumar, several safety considerations should be addressed.

- INR monitoring: regular blood tests are required to keep the International Normalized Ratio within the therapeutic range. - Surgical procedures: discontinue or adjust dose before elective surgery to minimise bleeding. - Liver disease: use with caution in patients with hepatic impairment, as metabolism may be altered. - Renal impairment: dose adjustments may be necessary for reduced kidney function. - Concomitant medications: inform healthcare providers of all drugs, especially antiplatelet agents or NSAIDs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Phenprocoumon interacts with many medicines, requiring careful management.

Major Interactions (Avoid): - Other vitamin K antagonists (e.g., warfarin): additive anticoagulant effect. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase plasma levels, raising bleeding risk. - NSAIDs (e.g., ibuprofen, naproxen): enhance gastrointestinal bleeding. - Antiplatelet agents (e.g., clopidogrel, aspirin): combined effect on hemostasis. - Vitamin K supplements or high‑vitamin K foods: reduce anticoagulant efficacy.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., macrolides, quinolones): may alter INR. - SSRIs and SNRIs: increase bleeding tendency. - Diuretics (e.g., furosemide): affect plasma protein binding. - Thyroid hormones: may potentiate anticoagulant effect. - Herbal products (e.g., ginkgo, garlic): possible enhancement of bleeding.